Velcade Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Effective venetoclax-based treatment in relapsed/refractory multiple myeloma patients with translocation t(6;14)
In this study, we conducted a retrospective analysis to investigate the efficacy of venetoclax-based therapy in relapsed/refractory myeloma patients with t(6;14) translocation. The treatment courses of three patients, that included previous therapies and responses to venetoclax, were assessed. Clinical data, laboratory results, and adverse events were analyzed to evaluate treatment outcomes. Results: Our findings demonstrated remarkable therapeutic responses in three consecutive patients with t(6;14) translocation-associated myeloma who received venetoclax-based therapy. Patient 1, a lenalidomide-bortezomib-daratumumab and...
Source: Pathology Oncology Research - November 29, 2023 Category: Pathology Authors: Andrea Cegl édi Zolt án Csukly M ónika Fekete Andr ás Kozma Zsuzsanna Szemlaky Hajnalka Andrikovics G ábor Mikala Source Type: research

Corrigendum to "Different roles of bortezomib and ONX 0914 in acute kidney injury" [Int. Immunopharmacol. 82 (2020) 106259]
Int Immunopharmacol. 2023 Nov 27:111189. doi: 10.1016/j.intimp.2023.111189. Online ahead of print.NO ABSTRACTPMID:38012900 | DOI:10.1016/j.intimp.2023.111189 (Source: International Immunopharmacology)
Source: International Immunopharmacology - November 28, 2023 Category: Allergy & Immunology Authors: Xing-Zhe Zhang Feng Han Chen-Guang Ding Meng Dou Yu-Xiang Wang Wu-Jun Xue Xiao-Ming Ding Jin Zheng Cui-Xiang Xu Pu-Xun Tian Source Type: research

Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation
ConclusionsOur estimates show that the combined test has a high probability of being cost effective. There is good quality evidence for the benefit of subtyping DLBCL but the evidence on the number of patients reclassified to or from BL and PMBCL and the impact of a more precise diagnosis and the cost of treatment is weak. The developers can use the price estimate to inform a return on investment calculations. Evidence will be required of how well the TempO-Seq® technology performs compared to the testing GEP technology used for subtyping in the recent clinical trial. For BL and PMBCL elements of the test, evidence would ...
Source: Applied Health Economics and Health Policy - November 28, 2023 Category: Health Management Source Type: research

Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation
In this study, we first report that DHCE shows antitumor activities in vitro and in vivo and exerts stronger inhibitory effects than celastrol on BTZ-R cells. We find that DHCE inhibits BTZ-R cell viability by promoting apoptosis via extrinsic and intrinsic pathways and suppresses BTZ-R MM cell proliferation by inducing G0/G1 phase cell cycle arrest. In addition, inactivation of JAK2/STAT3 and PI3K/Akt pathways are involved in the DHCE-mediated antitumor effect. Simultaneously, DHCE acts synergistically with BTZ on BTZ-R cells. PSMB5, a molecular target of BTZ, is overexpressed in BTZ-R MM cells compared with BTZ-S MM cell...
Source: Acta Biochimica et Biophysica Sinica - November 27, 2023 Category: Biochemistry Authors: Shuhan Jin Bo Li Bibo Zhang Xuejie Gao Xinyan Jia Li Xu Shuaikang Chang Ke Hu Guanli Wang Zhijian Xu Ting Zhang Dongliang Song Guang Yang Xiaosong Wu Huabin Zhu Cheng Huang Yumeng Lu Jumei Shi Weiliang Zhu Gege Chen Source Type: research

Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine
Curr Oncol. 2023 Nov 2;30(11):9676-9688. doi: 10.3390/curroncol30110702.ABSTRACTProteasome inhibitors are moieties targeting the proteolytic activity of a proteasome, with demonstrated efficacy in certain hematological malignancies and candidate drugs in other types of cancer, including glioblastoma (GBM). They disturb the levels of proteasome-regulated proteins and lead to the cell cycle inhibition and apoptosis of GBM cells. The accumulation of cell cycle inhibitors p21 and p27, and decreased levels of prosurvival molecules NFKB, survivin, and MGMT, underlie proteasome inhibitors' cytotoxicity when used alone or in combi...
Source: Current Oncology - November 24, 2023 Category: Cancer & Oncology Authors: Agata Gozdz Source Type: research

Proteasome Inhibitors against Glioblastoma-Overview of Molecular Mechanisms of Cytotoxicity, Progress in Clinical Trials, and Perspective for Use in Personalized Medicine
Curr Oncol. 2023 Nov 2;30(11):9676-9688. doi: 10.3390/curroncol30110702.ABSTRACTProteasome inhibitors are moieties targeting the proteolytic activity of a proteasome, with demonstrated efficacy in certain hematological malignancies and candidate drugs in other types of cancer, including glioblastoma (GBM). They disturb the levels of proteasome-regulated proteins and lead to the cell cycle inhibition and apoptosis of GBM cells. The accumulation of cell cycle inhibitors p21 and p27, and decreased levels of prosurvival molecules NFKB, survivin, and MGMT, underlie proteasome inhibitors' cytotoxicity when used alone or in combi...
Source: Cancer Control - November 24, 2023 Category: Cancer & Oncology Authors: Agata Gozdz Source Type: research